Apricus Biosciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Strong Long	2/17/2016 6:01:13 PM
	Read Replies (2) of 2026

Good posts here lately...as always. Good to see that IR gave some good (non press release) information Eman. The ensuing discussion about that subject on this board was very thought provoking. I hadn't looked at the RPRX pps in quite some time until today. Wow, trading below $1.00...what a fall it has taken this last year. I have always wondered, with Denner's reputation for his craft being what it is, did he have any insight that Repros would run into the trouble they did late in their Androxal review...regarding the bioanalytical method validation affecting interpretability of pivotal study data. Just took a look at Sarissa's investments again. With the recent APRI direct offering, Apricus is going to be way near the top of Sarissas holdings in terms of shares held. Does this guy think APRI is going to make him money? Rhetorical question! So how bad off are we that Denner positioned to get shares at bottom barrel prices. Pretty impressive whether it was orchestrated or as a result of shrewd, cunning maneuvering. I remember many were excited to see his arrival, maybe that doesn't have to change. Time will tell...hang in there OC and all. Been struggling with how to vote my shares...or not, good discussion MI. Best case scenario is what I believe has got to be the best choice, though anger and frustration with the current pps and company set backs certainly makes it difficult to stay focused on that. Many questions remain. What are Denner's intentions...how much money does he think can make here and how best to do that? Where does future financing for the pipeline come from if that is our path in the foreseeable future? How will the resubmitted NDA for Vitaros US turn out? How will delays in the room temp device effect milestones and Vitaros revenue streams? What will the modified versions of cold chain bring and is that why Germany is stalled. Canada? Never mind :) One last thought. The Fispemifine development really does sound very positive to me. It sounded like Pascoe could hardly restrain himself from speaking about the data they are obtaining in the P2B during the recent bio conference. Apricus seems to be working very closely with the FDA on this to ensure its success. It's got to be why Denner is so willing to gamble so much on our APRI.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next